» Articles » PMID: 26869265

The Accuracy and Completeness for Receipt of Colorectal Cancer Care Using Veterans Health Administration Administrative Data

Overview
Publisher Biomed Central
Specialty Health Services
Date 2016 Feb 13
PMID 26869265
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The National Comprehensive Cancer Network and the American Society of Clinical Oncology have established guidelines for the treatment and surveillance of colorectal cancer (CRC), respectively. Considering these guidelines, an accurate and efficient method is needed to measure receipt of care.

Methods: The accuracy and completeness of Veterans Health Administration (VA) administrative data were assessed by comparing them with data manually abstracted during the Colorectal Cancer Care Collaborative (C4) quality improvement initiative for 618 patients with stage I-III CRC.

Results: The VA administrative data contained gender, marital, and birth information for all patients but race information was missing for 62.1% of patients. The percent agreement for demographic variables ranged from 98.1-100%. The kappa statistic for receipt of treatments ranged from 0.21 to 0.60 and there was a 96.9% agreement for the date of surgical resection. The percentage of post-diagnosis surveillance events in C4 also in VA administrative data were 76.0% for colonoscopy, 84.6% for physician visit, and 26.3% for carcinoembryonic antigen (CEA) test.

Conclusions: VA administrative data are accurate and complete for non-race demographic variables, receipt of CRC treatment, colonoscopy, and physician visits; but alternative data sources may be necessary to capture patient race and receipt of CEA tests.

Citing Articles

Summary of Veterans Health Administration Cancer Data Sources.

Zullig L, Jazowski S, Chawla N, Williams C, Winski D, Slatore C J Registry Manag. 2024; 51(1):21-28.

PMID: 38881982 PMC: 11178113.


Association between imaging surveillance frequency and outcomes following surgical treatment of early-stage lung cancer.

Heiden B, Eaton D, Chang S, Yan Y, Schoen M, Thomas T J Natl Cancer Inst. 2022; 115(3):303-310.

PMID: 36442509 PMC: 9996218. DOI: 10.1093/jnci/djac208.


Relationship between S100A4 protein expression and pre-operative serum CA19.9 levels in pancreatic carcinoma and its prognostic significance.

Jia F, Liu M, Li X, Zhang F, Yue S, Liu J World J Surg Oncol. 2019; 17(1):163.

PMID: 31526392 PMC: 6747733. DOI: 10.1186/s12957-019-1707-4.

References
1.
Earle C, Nattinger A, Potosky A, Lang K, Mallick R, Berger M . Identifying cancer relapse using SEER-Medicare data. Med Care. 2002; 40(8 Suppl):IV-75-81. DOI: 10.1097/00005650-200208001-00011. View

2.
Nattinger A, Schapira M, Warren J, Earle C . Methodological issues in the use of administrative claims data to study surveillance after cancer treatment. Med Care. 2002; 40(8 Suppl):IV-69-74. DOI: 10.1097/00005650-200208001-00010. View

3.
Warren J, Harlan L, Fahey A, Virnig B, Freeman J, Klabunde C . Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002; 40(8 Suppl):IV-55-61. DOI: 10.1097/01.MLR.0000020944.17670.D7. View

4.
Virnig B, Warren J, Cooper G, Klabunde C, Schussler N, Freeman J . Studying radiation therapy using SEER-Medicare-linked data. Med Care. 2002; 40(8 Suppl):IV-49-54. DOI: 10.1097/00005650-200208001-00007. View

5.
Cooper G, Virnig B, Klabunde C, Schussler N, Freeman J, Warren J . Use of SEER-Medicare data for measuring cancer surgery. Med Care. 2002; 40(8 Suppl):IV-43-8. DOI: 10.1097/00005650-200208001-00006. View